What is C4 Therapeutics?
C4 Therapeutics is at the forefront of developing novel therapeutics by leveraging the power of targeted protein degradation (TPD). This cutting-edge technology aims to harness the cell's natural processes to selectively eliminate disease-causing proteins, offering a new modality for treating a wide range of conditions. The company's leadership comprises seasoned experts from leading biopharmaceutical organizations, bringing a wealth of experience in drug development, scientific research, and commercialization.
With a strategic focus on TPD, C4 Therapeutics is poised to address significant unmet medical needs across various therapeutic areas. The company's commitment to innovation and its robust scientific foundation are key drivers of its growth and its potential to reshape the future of medicine.
How much funding has C4 Therapeutics raised?
C4 Therapeutics has raised a total of $425M across 4 funding rounds:
Series A
$73M
Multiple Rounds
$352M
Series A (2016): $73M with participation from Novartis, The Kraft Group, Roche Holding AG, and EG Capital
Debt (2020): $20M led by Perceptive Advisors
Series B (2020): $150M supported by Commodore Capital Partners LLC, Axil Capital, Yonjin Venture LLC, Logos Capital LLC, RTW Investments , LP, Mizuho Securities Principal Investment Co. Ltd, Nextech Systems LLC, Cobro Ventures inc, HBM Healthcare Investments AG, Janus Henderson Group, Taiwania Capital, T. Rowe Price, Inc., RA Capital Management LP, 3E Bioventures Capital, ADAGE CAPITAL MANAGEMENT LP, and Sphera Fund Management Ltd
Stock Issuance/Offering (2020): $182M, investors not publicly disclosed
Key Investors in C4 Therapeutics
HBM Healthcare Investments AG
HBM Healthcare Investments AG is a publicly traded investment company focused on the global healthcare sector, specializing in funding innovative therapies and medical technologies. Their investment strategy emphasizes capitalizing on growth opportunities within the healthcare market through a diversified portfolio of private and public companies.
Taiwania Capital
Taiwania Capital is a venture capital firm that invests in early-stage companies, with a focus on enterprise software, AI, IoT, robotics, and next-gen semiconductors. They aim to identify and support startups with significant potential in these technology-driven sectors.
3E Bioventures Capital
3E Bioventures Capital operates with a science-driven, entrepreneur-friendly philosophy, focusing on developing drugs and products for unmet medical needs. They leverage their expertise, efficiency, and execution capabilities to advance companies across the Pacific.
What's next for C4 Therapeutics?
The substantial capital raised by C4 Therapeutics, particularly the recent major strategic investment, signals a pivotal phase for the company. This financing is expected to accelerate the advancement of its clinical programs, expand its research and development capabilities, and potentially broaden its therapeutic pipeline. The company is likely to focus on progressing its lead drug candidates through clinical trials, further validating its TPD platform, and exploring strategic partnerships to maximize the impact of its innovations.
As C4 Therapeutics moves forward, its strategic objective will be to translate its scientific breakthroughs into tangible patient benefits. The company's ability to attract significant investment from prominent backers highlights its potential to become a leader in the next wave of precision medicine, offering hope for more effective and targeted treatments.
